Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

CalTrack

  • Software package for high throughput automated analysis of cardiomyocyte calcium.
  • Extraction of calcium traces from fluorescent live cell microscopy videos.
  • Can meta-analyze traces from photomultiplier tube.
  • Compatibility with primary and stem cell derived cardiomyocytes, cardiomyocyte constructs and all fluorescent calcium reporters

CalTrack

Availability

Full written guide included with the software (training available). Requires MatLab license (currently provided free of charge university-wide).

Citation of original publication required:

https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.121.318868

Custom modifications possible (but not guaranteed) upon request.


Location

Level 5, West Wing,

John Radcliffe Hospital

Contact Yiangos Psaras

Example Data

CalTrack example data

CalTrack defines calcium phenotypes and drug responses in iPSC-CMs harboring the hypertrophic cardiomyopathy (HCM) TNNI3R21C/+ variant.

A, Averaged calcium transient traces of wild-type and TNNI3R21C/+ cardiomyocytes with 0.3 μM, 1 μM, and 3 μM mavacamten. B, Mavacamten reduces Fmax/F0 in a dose-dependent manner. C, Mavacamten has variable, dose-dependent effects on T50on (time to 50% calcium peak) in the TNNI3R21C/+ cardiomyocytes. D, time to reach calcium peak (Ton) is shortened in TNNI3R21C/+ cardiomyocytes by Mavacamten. E, Calcium decay constant (Tau) is shortened in TNNI3R21C/+ cardiomyocytes by increasing mavacamten dose. F, Calcium transient duration (CD) is reduced in TNNI3R21C/+ cardiomyocytes with increasing doses of mavacamten.